Ten years ago, The sales income of Beijing biomedical industry was less than 3.0 billion, while today, that is close to 30.0 billion. The bio-pharmaceutical industry of Chinese medicine has contributed to a profit of 14% from January to August this year. Bio-pharmaceutical profits preponderate over that of the traditional Chinese medicine for the first time; the R & D service industry grows fast and has been maintained above the 30% rate. The restructuring of biological medicine industry received good results. ABO, an important force of R & D service industry in Beijing area, has grown up to 28 members, with 5 more enterprises applicating, such as Amoytop & ASDI. ASDI is the first abroad enterprise applying for joining the alliance. Among the top 10 multinational pharmaceutical companies, 9 have become important customers of ABO. In addition, with the implementing of the national key programs on new drugs discovery and development, prevention and treatment of major infectious diseases and the transformal genetics research, the domestic needs for new drug research and development service will be more than the sum of the past 10 years. Furthermore, the establishment of the prevention and control system for Food security, emergency disease, has broadened the market of R&D service industry. Biotechnology R & D services has reached an important victory in Beijing. In the future, the HIF will continue to serve biomedical R & D service industry, and at the same time, keep promoting bio-industry, eco-industries, and the development of circular economy.
